These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 33960153)

  • 21. Effects of Withdrawing α1-Blocker from Combination Therapy with α1-Blocker and 5α-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics.
    Matsukawa Y; Takai S; Funahashi Y; Majima T; Kato M; Yamamoto T; Gotoh M
    J Urol; 2017 Oct; 198(4):905-912. PubMed ID: 28499730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of α-blocker monotherapy and α-blocker plus 5α-reductase inhibitor combination therapy based on prostate volume for treatment of benign prostatic hyperplasia.
    Joo KJ; Sung WS; Park SH; Yang WJ; Kim TH
    J Int Med Res; 2012; 40(3):899-908. PubMed ID: 22906262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of α-blocker and 5α-reductase inhibitor for treatment of benign prostatic hyperplasia.
    Kang D; Hu C; Fu Y; Wang D
    Clin Invest Med; 2017 Oct; 40(5):E200-E210. PubMed ID: 29061225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [REVIEW OF CLINICAL STUDIES ON COMBINATION THERAPY OF 5α-REDUCTASE INHIBITORS AND α1-BLOCKERS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA].
    Spivak LG; Lokshin KL; Vinarov AZ
    Urologiia; 2015; (4):125-33. PubMed ID: 26665780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medical therapy for benign prostatic hyperplasia: a review.
    Van Asseldonk B; Barkin J; Elterman DS
    Can J Urol; 2015 Oct; 22 Suppl 1():7-17. PubMed ID: 26497339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of single-dose tamsulosin and dutasteride combination therapy compared with tamsulosin monotherapy in patients with benign prostatic hyperplasia in the UK.
    Walker A; Doyle S; Posnett J; Hunjan M
    BJU Int; 2013 Sep; 112(5):638-46. PubMed ID: 23356792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Effectiveness of Combination Therapy Versus Monotherapy in Benign Prostatic Hyperplasia: A Colombian Experience.
    Guevara-Cuellar CA; Parody-Rúa E; Garcia-Perdomo HA; Arenas-Duque A
    Value Health Reg Issues; 2018 Dec; 17():174-182. PubMed ID: 30415110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacological treatment of benign prostatic hyperplasia].
    Oelke M; Martinelli E
    Urologe A; 2016 Jan; 55(1):81-94; quiz 95-6. PubMed ID: 26676726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.
    Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM
    BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
    Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
    BJU Int; 2019 Jul; 124(1):27-34. PubMed ID: 30681264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world use of Permixon® in benign prostatic hyperplasia--determining appropriate monotherapy and combination treatment.
    Perry R; Milligan G; Anderson P; Gillon A; White M
    Adv Ther; 2012 Jun; 29(6):538-50. PubMed ID: 22644964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Medical treatment of patients with benign prostatic hyperplasia with 5-reductase inhibitors].
    Spivak LG; Platonova DV; Yagudaev DD
    Urologiia; 2019 Sep; (4):175-179. PubMed ID: 31535827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Adding Dutasteride to α-Blocker Therapy Treated Benign Prostatic Hyperplasia Patients with Small Volume Prostate (<30 mL).
    Hashimoto M; Shimizu N; Sugimoto K; Hongoh S; Minami T; Nozawa M; Yoshimura K; Hirayama A; Tahara H; Uemura H
    Low Urin Tract Symptoms; 2017 Sep; 9(3):157-160. PubMed ID: 26991643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistence and adherence to dutasteride/tamsulosin fixed-dose versus free-combination alpha blocker/5ARI therapy in patients with benign prostate hyperplasia in Germany
.
    Eisen C; Lulic Z; Palacios-Moreno JM; Adalig B; Hennig M; Cortes V; Gilg F; Kostev K
    Int J Clin Pharmacol Ther; 2020 Jan; 58(1):37-49. PubMed ID: 31670653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination therapies for improved management of lower urinary tract symptoms/benign prostatic hyperplasia.
    De Nunzio C; Presicce F; Tubaro A
    Drugs Today (Barc); 2016 Sep; 52(9):501-517. PubMed ID: 27883117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient characteristics and treatment patterns for patients with benign prostatic hyperplasia, erectile dysfunction or co-occurring benign prostatic hyperplasia and erectile dysfunction in general practices in the UK: a retrospective observational study.
    Ilo D; Raluy-Callado M; Graham-Clarke P; Sadasivan R; Birt J; Donaldson R; Zhu E; Kirby MG; Neasham D
    Int J Clin Pract; 2015 Aug; 69(8):853-62. PubMed ID: 26011100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
    Silva J; Silva CM; Cruz F
    Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Impact of Combination Therapy with a-Blockers and 5ARIs on the Progression of BPH.
    Sountoulides P; Gravas S
    Curr Drug Targets; 2015; 16(11):1172-9. PubMed ID: 25706255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk stratification for benign prostatic hyperplasia (BPH) treatment.
    Emberton M; Fitzpatrick JM; Rees J
    BJU Int; 2011 Mar; 107(6):876-80. PubMed ID: 21265993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.